METheraHld (METX.CN)
| Previous Close | 3.5000 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 3.5000 - 3.5000 |
| 52 Week Range | 0.0500 - 7.5000 |
| Volume | |
| Avg. Volume | 1,034 |
| Market Cap | 88.163M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileME Therapeutics Holdings Inc. Appoints Chief Business Officer
Vancouver, British Columbia--(Newsfile Corp. - October 25, 2024) - ME Therapeutics Holdings Inc. (CSE:METX) (FSE:Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to announce the appointment of Karim Lalji as Chief Business Officer. "We are excited to be able to announce the addition of Karim Lalji as Chief Business Officer," said Salim Dhanji, PhD, Chief Executive Officer of ...
NewsfileME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to update investors on the progress of our research and development and corporate development plans. G-CSF Antibody Candidate UpdateThe Company is continuing to advance our lead anti-G-CSF antibody candidate, h1B11-12
